ABSTRACT
Background@#Pre-eclampsia is a multi-organ progressive disorder that is estimated to complicate 2 to 8% of pregnancies. Numerous studies on prophylactic aspirin intake among high-risk pregnant women has been established but studies involving low-risk primigravida women are limited.@*Objectives@#To determine if prophylactic intake of aspirin will reduce the occurrence of preeclampsia among primigravida women with no identified comorbidities and to determine the incidence and association of identified secondary outcomes.@*Methodology@#This retrospective cohort study was conducted from January 2018 to December 2020 in two (2) tertiary hospitals in the province of Cavite. Two hundred four (204) primigravida women with no identified co-morbidities and delivered to a singleton fetus, vaginally or operatively, were identified and included. In-patient and out-patient charts of primigravida women, with aspirin intake versus no aspirin intake, were reviewed. Primary outcome (pregnancy induced hypertension) and secondary outcomes (preterm delivery, small-for-gestational age infants, IUFD, HELLP syndrome and abruption placenta) were identified.@*Results@#The mean age of patients was 27.1 years and 25.9 years in the aspirin and non-aspirin group, respectively. In aspirin group, 4.9% of the patients developed pre-eclampsia versus 9.8% in non-aspirin group showing statistical significance. The effect of aspirin across other hypertensive disorders of pregnancy were noted to be the same. However, influence of aspirin with the average blood pressure on admission and secondary outcomes were not statistically significant.@*Conclusion@#CONCLUSION: Prophylactic aspirin intake has a significant effect in preventing pre-eclampsia among non-high risk primigravida women but did not influence the average blood pressure on admission, development of preterm PIH, and development of the secondary outcomes.